anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a Single-centered, Prospective, Observational Study. The study design included two phases. In Phase I, the investigators enrolled a set of consecutive patients with non-ischemic cardiomyopathy who performed contrast-enhanced cardiac magnetic resonance at baseline and had severe cardiac dysfunction (defined as cardiac magnetic resonance LVEF equal or less than 35% ) in FuWai Hospital from 2010 to 2013. The investigators collect patients' clinical baseline data and cardiac magnetic resonance specific data(Late gadolinium enhancement mass). All patients were followed up every six month by phone or clinical visits. The primary endpoint was composite of sudden cardiac death(SCD), ventricular arrhythmias(VAs) and SCD/VAs related Implantable Cardioverter defibrillator or cardiac resynchronization therapy-cardioverter defibrillator(ICD/CRTD) shock. The investigators plan to establish a quantitative LGE mass based model (including LGE mass on cardiac magnetic resonance, clinical features, specific medical histories, et al) for risk prediction of sudden cardiac death by analysing the phase I data(1-year model and 3-year model). In Phase II,the investigators will enroll another group of non-ischemic cardiomyopathy(NICM) patients from 2014 to 2015 to testify the risk prediction model(1-year model) the investigators have constructed in phase I. The investigators aim to find the real high risk NICM patients that may suffer from SCD or VAs in those with severe cardiac dysfunction.
A composition for controlling or preventing progression of glaucoma comprises a material that reduces or inhibits production of a TGF-.beta. isoform or a chemokine or cytokine that stimulates expression of a TGF-.beta. isoform. The material can comprise a dissociated glucocorticoid receptor agonist ("DIGRA"), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can further comprise an antagonist to TGF-.beta.. It is administered to a patient who has undergone glaucoma filtration surgery to ensure a functioning filtering bleb following such surgery.
Participants will be randomly assigned to SL-BUP with approximately 48 in the SL-BUP condition. The SL-BUP condition will use sublingual buprenorphine-naloxone, with a target maintenance daily dose range of 16-24mg as recommended for clinical practice. Titration to maintenance dosage will be attempted within the first two weeks of the SL-BUP condition. During the initial stabilization weeks, SL-BUP will be flexibly dosed as clinically indicated to relieve cravings and withdrawal symptoms, after which dosage adjustments will be based on clinical decisions by the site clinicians. The maintenance dosage of SL-BUP will be dispensed on a schedule similar to the XR-BUP injections (i.e., at approximately Day 14, Week 6, and Week 10).
Bottles of 30 Tablets (84460-901-30). Tablet is light blue, oblong.

*Florrax Pharmaceuticals does not represent this products code to be National Drug Code (NDC). Products codes are formatted according to standard industry practice, to meet the formatting requirement by pedigree reporting and supply-chain control including pharmacies.   
This products is a prescription-folate with or without other dietary ingredients the - due to increased folate levels increased risk associated with masking B12 deficiency (pernicious anemia) requires administration under the care of a licensed medical practitioner(64 FR 8760). 1-3 the most appropriate way to ensure pedigree reporting consistent with these regulatory guidelines and safety monitoring is to dispense this product only by prescription. This is not an Orange Book product. This product may be administered only under a physician's supervision and all prescriptions using this product shall be pursuant to state statues as applicable. The ingredients, indication or claims of this product are not to be construed to be Drug claims. 

1.) Federal register Notice of August 2, 1973 (39 FR 20750)   
2.) Federal Register Notice of October 17, 1980 (45 FR 69043, 69044) 

3.) Federal register notice of March 5, 1996 (61 FR 8760)
PURPOSE:To provide the titled composition having excellent quality and long- term stability, by drying a mixture of a fat emulsion and an aqueous solution of soluble carbohydrate, and using the product as a component of a nutrient composition containing at least fat and soluble carbohydrate. CONSTITUTION:The objective powdery nutrient composition containing at least fat and a soluble carbohydate is prepared by using a dried mixtur of (a) emulsion of fat such as vegetable oil, e.g. soybean oil, corn oil, cottonseed oil, etc. and (b) an aqueous solution of a soluble carbohydrate such as dextrin, monosaccharide, oligosaccharide, etc. as an essential component, and preferably adding at least one of amino acids, vitamins or minerals as another nutrient substance. Th nutrient composition has remarkably improved powder fluidity, contains increased amount of minor nutrient components, and exhibits remarkably improved emulsion stability when dissolved in water before use. The nutrient substance, e.g. fat, of the composition can be digested without trouble.
1. A compound having the structural formula: where R: 2. A compound of claim 1 having the structural formula: 3. A compound of claim 1 having the structural formula: 4. A compound of claim 1 having the structural formula: 5. A compound of claim 1 having the structural formula: 6. A compound of claim 1 having the structural formula: 7. A compound of claim 1 having the structural formula: 8. A compound of claim 1 having the structural formula: 9. A compound of claim 1 having the structural formula: 10. A compound of claim 1 having the structural formula: 11. A compound of claim 1 having the structural formula: 12. A compound of claim 1 having the structural formula: 13. A compound of claim 1 having the structural formula: 14. A compound of claim 1 having the structural formula: 15. A compound having the structural formula: where R: 16. A compound of claim 15 having the structural formula: 17. A compound of claim 15 having the structural formula: 18. A compound selected from the group comprising: and 19. A pharmaceutical composition comprising a compound in an anti-hyperlipidemic effective amount of any one of claims 1 to 18, and a pharmaceutically acceptable carrier. 20. A pharmaceutical composition comprising a compound in an anti-atherosclerotic effective amount of any one of claims1 to 18 and a pharmaceutically acceptable carrier. 21. A pharmaceutical composition comprising a compound an anti-hypercholesterolemia effective amount of any one of claims 1 to 18, and a pharmaceutically acceptable carrier. 22. A method for the prophylaxis or treatment of a hyperlipidemic condition comprising administering to a patient in need thereof a composition of claim 19 in unit dosage form. 23. A method for the prophylaxis or treatment of an atherosclerotic condition comprising administering to a patient in need thereof a composition of claim 19 unit dosage form. 24. A method for the prophylaxis or treatment of hypercholesterolemia comprising administering to a patient in need thereof a composition of claim 19 in unit dosage form. 25. Use of a compound of any one of claims 1 to 18 in the preparation of a medicament for use in the prophylaxis or treatment of a hyperlipidemic condition. 26. Use of a compound of any one of claims 1 to 18 in the preparation of a medicament for use in the prophylaxis or treatment of an atherosclerotic condition. 27. Use of a compound of any one of claims 1 to 18 in the preparation of a medicament for use in the prophylaxis or treatment of hypercholesterolemia condition.
AIMS: Coronary artery calcium score (CACS) and polygenic risk score have been used as novel markers to predict cardiovascular (CV) events of asymptomatic individuals compared with traditional scores. No previous studies have directly compared the additive capacity of these two markers relative to conventional scores. The aim of the study was to evaluate the change in CV risk prediction ability when CACS, genetic risk score (GRS), or both are added to Systematic Coronary Risk Evaluation 2 (SCORE2).
METHODS AND RESULTS: In a prospective, observational population-based study, 1002 asymptomatic subjects (mean age 53.1 ± 6.8 years, 73.8% male), free of clinical coronary disease and diabetes, were selected from GENEMACOR-study controls. SCORE2, CACS, and GRS were estimated to evaluate CV events' predictive and discriminative ability through Harrell's C-statistics. Net reclassification improvement (NRI) and integrated discrimination index were used to reclassify the population. Multivariable Cox proportional hazard ratio (HR) analysis assessed the variables independently associated with CV events. C-statistic demonstrated that the discriminative value for CV event occurrence was 0.608 for SCORE2, increasing to 0.749 (P = 0.001) when CACS was added, and improved to 0.802 (P = 0.0008) with GRS, showing a better discriminative capacity for CV events. Continuous NRI reclassified >70% of the population. Cox proportional analysis showed that the highest categories of SCORE2, CACS, and GRS remained in the equation with an HR of 2.9 (P = 0.003), 5.0 (P < 0.0001), and 3.2 (P = 0.003), respectively, when compared with the lowest categories.
CONCLUSION: In our population, CACS added to SCORE2 had better ability than GRS in CV event risk prediction, discrimination, and reclassification. However, adding the three scores can become clinically relevant, especially in intermediate-risk persons.
PURPOSE: Preoperative prediction of postoperative complications (PCs) in inpatients with cancer is challenging. We developed an explainable machine learning (ML) model to predict PCs in a heterogenous population of inpatients with cancer undergoing same-hospitalization major operations.
METHODS: Consecutive inpatients who underwent same-hospitalization operations from December 2017 to June 2021 at a single institution were retrospectively reviewed. The ML model was developed and tested using electronic health record (EHR) data to predict 30-day PCs for patients with Clavien-Dindo grade 3 or higher (CD 3+) per the CD classification system. Model performance was assessed using area under the receiver operating characteristic curve (AUROC), area under the precision recall curve (AUPRC), and calibration plots. Model explanation was performed using the Shapley additive explanations (SHAP) method at cohort and individual operation levels.
RESULTS: A total of 988 operations in 827 inpatients were included. The ML model was trained using 788 operations and tested using a holdout set of 200 operations. The CD 3+ complication rates were 28.6% and 27.5% in the training and holdout test sets, respectively. Training and holdout test sets' model performance in predicting CD 3+ complications yielded an AUROC of 0.77 and 0.73 and an AUPRC of 0.56 and 0.52, respectively. Calibration plots demonstrated good reliability. The SHAP method identified features and the contributions of the features to the risk of PCs.
CONCLUSION: We trained and tested an explainable ML model to predict the risk of developing PCs in patients with cancer. Using patient-specific EHR data, the ML model accurately discriminated the risk of developing CD 3+ complications and displayed top features at the individual operation and cohort level.
BACKGROUND Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome is an autoinflammatory fever syndrome primarily seen in children under age 5 years, and its etiology is unknown. Most cases are resolved by the age of 10 years, and it is rare in adults. PFAPA is characterized by recurrent episodes of fever associated with pharyngitis, stomatitis, and cervical adenitis, although not all clinical features are present at initial evaluation. Diagnosis is made clinically, as there are no specific biomarkers available. Treatment includes prednisone, colchicine, interleukin-1 blockers, and tonsillectomy. We report a case of adult-onset PFAPA syndrome that responded to colchicine. CASE REPORT A 22-year-old woman presented to the Rheumatology Clinic for evaluation of recurrent fevers associated with sore throat and enlarged painful cervical lymph nodes. She was symptom-free between the episodes. Workup for infectious causes and autoinflammatory/autoimmune diseases was unremarkable. Various differential diagnoses were considered, due to her unusual presentation. After all were ruled out, PFAPA was diagnosed based on her symptoms, and she started steroids, to which she had a dramatic response and resolution of symptoms. She was then transitioned to oral colchicine, which significantly decreased flare frequency. CONCLUSIONS Being aware of PFAPA syndrome in adults is vital. A timely diagnosis can significantly improve a patient's quality of life. This case highlights the importance of considering PFAPA syndrome in the differential diagnosis of periodic febrile illnesses in adults and the role of Colchicine as prophylaxis. Larger studies are needed to understand etiopathogenesis better and develop other effective therapeutics.
The invention discloses the application of general anesthetic to preparation of drugs for treating gout. The general anesthetic is prepared through uniform mixing of 0.3-99.7 parts by weight of hemp fructus cannabis extract and 99.7-0.3 part by weight of hemp cannabinoid. Experiments prove that the general anesthetic has a great anti-gout effect, can remarkably reduce the level of serum uric acid of mice suffering from hyperuricemia, does not affect the level of serum uric acid of normal mice obviously, can remarkably restrain toe swelling induced by sodium urate, has activity similar to that of allopurinol, and has a small toxic or side effect. The general anesthetic has definite gout treating and preventing effects. The invention further provides a pharmaceutic preparation containing the general anesthetic for treating gout, and a corresponding dosage form. The general anesthetic can be made into clinically used drugs of various dosage forms with conventional preparing methods, and is convenient to use.
PURPOSE: Near-infrared fluorescence imaging using indocyanine green (ICG-NIFI) can visualize a blood flow in reconstructed gastric tube; however, it depends on surgeon's visual assessment. The aim of this study was to re-analyze the ICG-NIFI data by an evaluator independent from the surgeon and feasibility of creating the time-intensity curve (TIC).
METHODS: We retrospectively reviewed 97 patients who underwent esophageal surgery with gastric tube reconstruction between January 2017 and November 2022. From the stored ICG videos, fluorescence intensity was examined in the four regions of interest (ROIs), which was set around the planned anastomosis site on the elevated gastric tube. After creation the TICs using the OpenCV library, we measured the intensity starting point and time constant and assessed the correlation between the anastomotic leakage.
RESULTS: Postoperative leakage occurred for 12 patients. The leakage group had significantly lack of blood flow continuity between the right and left gastroepiploic arteries (75.0% vs. 22.4%; P < 0.001) and tended to have slower ICG visualization time assessed by the surgeon's eyes (40 vs. 32 s; P = 0.066). TIC could create in 65 cases. Intensity starting point at all ROIs was faster than the surgeon's assessment. The leakage group tended to have slower intensity starting point at ROI 3 compared to those in the non-leakage group (22.5 vs. 19.0 s; P = 0.087).
CONCLUSION: A TIC analysis of ICG-NIFI by an independent evaluator was able to quantify the fluorescence intensity changes that the surgeon had visually determined.
MSCs will be used to treat refractory CMV infection or CMV-associated diseases. MSCs will be intravenously infused at a dose of 1×10\^6 cells/kg. If anticipates do not attain the complete remission standards within 14d, a second course of the same treatment will be given.
The following applications will be made 10 minutes before the patients in the acupressure group. Hands are washed before applying acupressure. Before acupressure is applied, the patient is allowed to sit in a comfortable position on the sofa in the single blood collection room. Before starting the acupressure application, the arm is rubbed from fingertips to the elbow to relax, and press the acupressure points (Large Intestine Meridian 4th Point \[LI 4\], Large Intestine Meridian 11th Point \[LI 11\], and Heart Meridian 7th Point \[HT 7\]). application is carried out. 2 minutes to each acupressure point. pressure (3 to 5 kg of pressure) is applied. Only one acupressure session is given to each patient, and each acupressure session lasts 10 minutes. Venipuncture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 \* 38 mm (21G x 1½, green).
The invention relates to a Chinese patent medicine, and especially relates to a Chinese patent medicine used for increasing leucocytes and enhancing immunity. The Chinese patent medicine is prepared from raw materials of, by weight: 120 to 180 parts of rehmannia dride rhizome, 90 to 150 parts of Tuckahoe, 170 to 230 parts of salvia miltiorrhiza, 90 to 150 parts of arisaema erubescens, 550 to 650 parts of sinomenium acutum, 70 to 130 parts of licorice, 90 to 150 parts of white peony root, 70 to 130 parts of swordlike atractylodes rhizome, and 70 to 130 parts of boehmeria nivea. The Chinese patent medicine provided by the invention is completely composed of Chinese herbal medicines. The Chinese patent medicine has advantages of good curative effect, fast effect, low treatment cost, and no side-effect. The medicine is safe to take. The Chinese patent medicine is suitable to be used for treating leucopenia caused by cancer-treating chemoradiation or unidentified reasons. The Chinese patent medicine provides functions of appetite promoting, immunity enhancing, intestine and stomach cleaning, bowel relaxing, toxicant elimination, pain relieving, qi and blood nourishing, and blood circulation enhancing. The cost of the Chinese patent medicine is low, and the medicine is easy to take.
Astragali radix (AR) and anemarrhenae rhizoma (AAR) are used clinically in Chinese medicine for the treatment of chronic heart failure (CHF), but the exact therapeutic mechanism is unclear. In this study, a total of 60 male C57BL/6 mice were divided into 5 groups, namely sham, model, AR, AAR, and AR-AAR. In the sham group, the chest was opened without ligation. In the other groups, the chest was opened and the transverse aorta was ligated to construct the transverse aortic constriction model. After 8 weeks of feeding, mice were given medicines by gavage for 4 weeks. Left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were detected by echocardiography. Heart weight index (HWI) and wheat germ agglutinin staining were used to evaluate cardiac hypertrophy. Hematoxylin-eosin staining was used to observe the pathological morphology of myocardial tissue. Masson staining was used to evaluate myocardial fibrosis. The content of serum brain natriuretic peptide (BNP) was detected by enzyme-linked immunosorbent assay kit. The content of serum immunoglobulin G (IgG) was detected by immunoturbidimetry. The mechanism of AR-AAR in the treatment of CHF was explored by proteomics. Western blot was used to detect the protein expressions of complement component 1s (C1s), complement component 9 (C9), and terminal complement complex 5b-9 (C5b-9). The results show that AR-AAR inhibits the expression of complement proteins C1s, C9, and C5b-9 by inhibiting the production of IgG antibodies from B cell activation, which further inhibits the complement activation, attenuates myocardial fibrosis, reduces HWI and cardiomyocyte cross-sectional area, improves cardiomyocyte injury, reduces serum BNP release, elevates LVEF and LVFS, improves cardiac function, and exerts myocardial protection.
PURPOSE:To obtain a collagenase inhibitor useful for preventing metastasis of cancer and treating rheumatoid arthritis, comprising a 8-hydroxyquinoline derivative as an active ingredient. CONSTITUTION:A collagenase inhibitor of the compound (R1 is H, OH, halogen, amino, nitro, sulfate or lower alkyl; R2 is H, halogen or lower alkyl; R3 is H, halogen, carboxyl, etc.; R4 is H, OH or halogen) and its salt as an active ingredient. 8-Hydroxyquinaldine may be cited as the compound of the formula. The collagenase inhibitor is pharmaceutically manufactured into agent, injection, suppository or enteric agent. The dose is 10-500mg daily. The compound of the formula is a well-known compound, sold on the market and is readily obtainable.
The women in the 1st group will be pre-tested with data collection tools before the HSG, then after they are taken to the table, headphones will be put on and music will be played. VAS and State-Trait Anxiety Inventory will be applied after the procedure. After 24 hours, the women will be reached and questioned whether they use analgesics. After the women in this group are completed, the 2nd group will be started.
Cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS) and disease spectrum is an autosomal recessive disorder associated with biallelic repeat expansion (RE) in the RFC1 gene. A high carrier frequency in the healthy population determines the possibility of having affected members in two consecutive generations. We describe pseudodominance in two families affected with RFC1 disorder (10 affected, 5 oligo/asymptomatic individuals). In Family A, after the 75-year-old index case was diagnosed with CANVAS, the 73-year-old wife decided to undergo screening for carrier testing. Although she did not report any symptoms, she resulted positive for the biallelic AAGGG RE thus leading to a diagnosis in the asymptomatic offspring as well and revealing a pseudodominant pattern of inheritance. In Family B pseudodominance was suspected after the identification of the RFC1 RE in the proband affected by sensitive neuropathy because of a positive family history for undetermined polyneuropathy in the mother. The post-mortem identification of the RFC1 RE in a sample specimen from the deceased mother, who had been under our care, allowed the solution of a "cold case". Our report suggests that pseudodominance is a confounding phenomenon to consider in RFC1-spectrum disorder and genetic counselling is instrumental in families with affected individuals.
External guide sequence (EGS) molecules for eukaryotic RNAse P are engineered to target efficient and specific cleavage of target RNA. Engineered RNA molecules are designed and synthesized which contain specific nucleotide sequences which enable an external guide sequence for RNAse P to preferentially bind to and promote RNAse P-mediated cleavage of target RNA molecules. Short External Guide Sequence (SEGS) molecules have been constructed that, when hybridized to a target molecule, provide a minimal structure recognized as a substrate by RNAse P. The SEGS/target structure is comprised of structures similar to the A stem and the T stem of a tRNA, the natural substrate of RNAse P. The SEGS makes up only half of these stem structures. The other half of the stem structures is provided by the target molecule. By allowing the target molecule to form more of the RNAse P substrate structure, the disclosed SEGS molecules can be significantly smaller than previous EGS molecules. This makes SEGS molecules especially useful as therapeutic agents since they are easier to manufacture and administer in quantity.
Participants will be administered first dose of HZ/su vaccine and the RSVPreF3 OA investigational vaccine together on Day 1. A second dose of the HZ/su vaccine will be administered at Day 61.
The duration of therapy was 12 sessions performed over a 6-week period. Each session lasted 30 minutes. They were performed individually by a speech-experienced therapist previously trained in Melodic Intonation Therapy.